Immune checkpoint inhibitors (ICIs) targeting programmed cell death 1 (PD-1), programmed cell death ligand 1 (PD-L1), or cytotoxic T lymphocyte antigen 4 (CTLA4), has been become one of the most important breakthroughs in cancer therapy (1). This evidence concerns the gene CD274 and cancer.